Compare · BON vs DFTX
BON vs DFTX
Side-by-side comparison of Bon Natural Life Limited (BON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.10B, about 548.6x BON ($9.3M).
- Over the past year, BON is down 40.6% and DFTX is up 308.3% - DFTX leads by 348.9 points.
- DFTX has hit the wire 7 times in the past 4 weeks while BON has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for BON).
PerformanceBON-40.63%DFTX+294.15%
2025-09-10+0.00%2026-09-09
- Company
- Bon Natural Life Limited
- Definium Therapeutics Inc.
- Price
- $1.14+0.44%
- $38.09+0.11%
- Market cap
- $9.3M
- $5.10B
- 1M return
- +4.59%
- -6.87%
- 1Y return
- -40.63%
- +308.31%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 7
Latest BON
- SEC Form 3 filed by new insider Zhixiang Gao
- SEC Form 3 filed by new insider Chen Jing Veronica
- SEC Form 3 filed by new insider Hu Yongwei
- SEC Form 3 filed by new insider Xue Yingchun
- SEC Form 3 filed by new insider Ma Xin
- SEC Form 3 filed by new insider Wenjuan Chen
- SEC Form 3 filed by new insider Liu Jing
- SEC Form 3 filed by new insider Gao Jianjun
- BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
- SEC Form 6-K filed by Bon Natural Life Limited
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)